{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.6","upperLimit":"67.6","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"The Kaplan-Meier method will be used to estimate the 6 month PFS. PFS is defined as time from initiation of protocol treatment to disease progression, recurrence, death from any cause, or date of last contact.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Olaparib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 6 months from study entry","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}